NASDAQ · RGNX
Healthcare · Biotechnology
$7.17
Down-$0.18 (-2.51%)
Updated Oct 23, 2026, 1:34 PM
SID Score
3.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · RGNX
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 22, 2026
RGNX closed at $7.17 after 21 trading sessions, down 0.97% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 22, 2026 | $7.11 | $7.305 | $6.98 | $7.17 | 1.13M |
| Oct 21, 2026 | $7.42 | $7.47 | $7.15 | $7.17 | 945.33K |
| Oct 20, 2026 | $7.15 | $7.58 | $7.06 | $7.40 | 1.32M |
| Oct 19, 2026 | $6.98 | $7.265 | $6.95 | $7.15 | 1.3M |
| Oct 16, 2026 | $7.14 | $7.18 | $6.875 | $6.925 | 1.21M |
| Oct 15, 2026 | $6.88 | $7.28 | $6.83 | $7.16 | 1.23M |
| Oct 14, 2026 | $7.12 | $7.24 | $6.80 | $6.88 | 1.57M |
| Oct 13, 2026 | $7.66 | $7.72 | $7.11 | $7.26 | 1.38M |
| Oct 12, 2026 | $8.12 | $8.29 | $7.74 | $7.77 | 2.03M |
| Oct 9, 2026 | $8.03 | $8.275 | $7.95 | $8.07 | 859.29K |
| Oct 8, 2026 | $7.50 | $8.31 | $7.44 | $8.09 | 2.26M |
| Oct 7, 2026 | $7.31 | $7.73 | $7.20 | $7.595 | 1M |
| Oct 6, 2026 | $7.79 | $7.84 | $7.33 | $7.45 | 1.16M |
| Oct 5, 2026 | $7.80 | $8.16 | $7.57 | $7.76 | 2.35M |
| Oct 2, 2026 | $7.58 | $7.62 | $7.36 | $7.43 | 1.04M |
| Oct 1, 2026 | $7.52 | $7.7363 | $7.30 | $7.42 | 1.71M |
| Sep 30, 2026 | $7.49 | $7.86 | $7.35 | $7.53 | 1.79M |
| Sep 29, 2026 | $7.41 | $7.64 | $7.33 | $7.45 | 2.1M |
| Sep 28, 2026 | $7.30 | $7.495 | $7.1701 | $7.47 | 1.33M |
| Sep 25, 2026 | $7.53 | $7.675 | $7.165 | $7.40 | 1.28M |
| Sep 24, 2026 | $7.45 | $7.46 | $7.12 | $7.24 | 1.52M |
The latest Smart Investors Daily articles mentioning RGNX.
Company
Market Activity
Research & News
RGNX research
Company profile and research snapshot.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 5, 2026 | Mizuho | Outperform | — |
| Aug 25, 2026 | Baird | Outperform | — |
| Aug 25, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 10, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 7, 2026 | Barclays | Equal-Weight | — |
Generated Oct 23, 2026, 1:16 PM
REGENXBIO Inc. held a discussion on clinical program progress and commercial outlook, providing stakeholders with insights into its pipeline developments in wet age-related macular degeneration (AMD) and rare diseases. The neutral sentiment around this disclosure suggests the market is evaluating the company's strategic positioning and the viability of its therapeutic programs.
Bottom line: REGENXBIO's clinical update reflects a company executing on its gene therapy strategy across multiple indications, though success remains unproven. Investors should monitor upcoming trial data closely, as concrete clinical evidence will be far more determinative of value than current strategic discussions. The risk-reward profile remains speculative until meaningful efficacy data emerges from wet AMD and rare disease programs.
SeekingAlpha · Oct 21, 2026
REGENXBIO Inc. (RGNX) Discusses Clinical Program Progress and Commercial Outlook in Wet AMD and Rare Diseases October 20, 2026 1:00 PM EDTCompany...
Yahoo · Oct 12, 2026
REGENXBIO Inc. (Nasdaq: RGNX) today announced it will host an investor event at 1:00 p.m. ET on Tuesday, October 20, 2026 to review the surabgene lomparvovec (sura-vec, ABBV-RGX-314) clinical program in wet age-related macular degeneration (wet AMD) ahead of the topline pivotal data anticipated in the fourth quarter of 2026. The event will be held in-person in New York, NY and available via webcast.
Yahoo · Oct 5, 2026
Mizuho initiated coverage of Regenxbio with an ‘Outperform’ rating and a $22 price target.
Benzinga · Oct 5, 2026
Regenxbio (NASDAQ:RGNX) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For real-time access to
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning RGNX.
